Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

K Groen; FH Schjesvold; B van der Holt; MD Levin; MR Seefat; M Hansson; MBL Leys; JC Regelink; A Waage; D Szatkowski; P Axelsson; TH Do; A Svirskaite; E van der Spek; E Haukas; D Knut-Bojanowska; PF Ypma; CH Blimark; UH Mellqvist; NWCJ van de Donk; P Sonneveld; A Klostergaard; AJ Vangsted; N Abildgaard; S Zweegman

doi:10.1097/hs9.0000000000000940

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

K Groen^*, FH Schjesvold, B van der Holt, MD Levin, MR Seefat, M Hansson, MBL Leys, JC Regelink, A Waage, D Szatkowski, P Axelsson, TH Do, A Svirskaite, E van der Spek, E Haukas, D Knut-Bojanowska, PF Ypma, CH Blimark, UH Mellqvist, NWCJ van de DonkP Sonneveld, A Klostergaard, AJ Vangsted, N Abildgaard, S Zweegman

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

11 Downloads (Pure)

Original language	English
Pages (from-to)	E940
Number of pages	4
Journal	HemaSphere
Volume	7
Issue number	9
DOIs	https://doi.org/10.1097/hs9.0000000000000940
Publication status	Published - 30 Sept 2023

Bibliographical note

Funding Information:
This study had partial research funding from Takeda Pharmaceutical Company Limited.

Access to Document

10.1097/hs9.0000000000000940Licence: CC BY-NC-ND

ixazomib_thalidomide_dexamethasone_induction.10Final published version, 709 KBLicence: CC BY-NC-ND

Cite this

Groen, K., Schjesvold, FH., van der Holt, B., Levin, MD., Seefat, MR., Hansson, M., Leys, MBL., Regelink, JC., Waage, A., Szatkowski, D., Axelsson, P., Do, TH., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, PF., Blimark, CH., Mellqvist, UH., ... Zweegman, S. (2023). Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. HemaSphere, 7(9), E940. https://doi.org/10.1097/hs9.0000000000000940

@article{89d200ec29814574867a20840e48886a,

title = "Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13",

author = "K Groen and FH Schjesvold and {van der Holt}, B and MD Levin and MR Seefat and M Hansson and MBL Leys and JC Regelink and A Waage and D Szatkowski and P Axelsson and TH Do and A Svirskaite and {van der Spek}, E and E Haukas and D Knut-Bojanowska and PF Ypma and CH Blimark and UH Mellqvist and {van de Donk}, NWCJ and P Sonneveld and A Klostergaard and AJ Vangsted and N Abildgaard and S Zweegman",

note = "Funding Information: This study had partial research funding from Takeda Pharmaceutical Company Limited.",

year = "2023",

month = sep,

day = "30",

doi = "10.1097/hs9.0000000000000940",

language = "English",

volume = "7",

pages = "E940",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "John Wiley & Sons Inc.",

number = "9",

}

Groen, K, Schjesvold, FH, van der Holt, B , Levin, MD, Seefat, MR, Hansson, M, Leys, MBL, Regelink, JC, Waage, A, Szatkowski, D, Axelsson, P, Do, TH, Svirskaite, A, van der Spek, E, Haukas, E, Knut-Bojanowska, D, Ypma, PF, Blimark, CH, Mellqvist, UH, van de Donk, NWCJ, Sonneveld, P, Klostergaard, A, Vangsted, AJ, Abildgaard, N & Zweegman, S 2023, 'Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13', HemaSphere, vol. 7, no. 9, pp. E940. https://doi.org/10.1097/hs9.0000000000000940

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. / Groen, K; Schjesvold, FH; van der Holt, B et al.
In: HemaSphere, Vol. 7, No. 9, 30.09.2023, p. E940.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients

T2 - Long-term Results of HOVON-126/NMSG 21.13

AU - Groen, K

AU - Schjesvold, FH

AU - van der Holt, B

AU - Levin, MD

AU - Seefat, MR

AU - Hansson, M

AU - Leys, MBL

AU - Regelink, JC

AU - Waage, A

AU - Szatkowski, D

AU - Axelsson, P

AU - Do, TH

AU - Svirskaite, A

AU - van der Spek, E

AU - Haukas, E

AU - Knut-Bojanowska, D

AU - Ypma, PF

AU - Blimark, CH

AU - Mellqvist, UH

AU - van de Donk, NWCJ

AU - Sonneveld, P

AU - Klostergaard, A

AU - Vangsted, AJ

AU - Abildgaard, N

AU - Zweegman, S

N1 - Funding Information: This study had partial research funding from Takeda Pharmaceutical Company Limited.

PY - 2023/9/30

Y1 - 2023/9/30

UR - http://www.scopus.com/inward/record.url?scp=85171177792&partnerID=8YFLogxK

U2 - 10.1097/hs9.0000000000000940

DO - 10.1097/hs9.0000000000000940

M3 - Article

C2 - 37663673

SN - 2572-9241

VL - 7

SP - E940

JO - HemaSphere

JF - HemaSphere

IS - 9

ER -

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Bibliographical note

Access to Document

Other files and links

Cite this